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ABSTRACT
	 Low-grade	 serous	 carcinoma	 is	one	of	 the	five	major	histological	 types	of	ovarian	
carcinoma	associated	with	a	specific	biology.	We	reviewed	three	cases	from	our	institution	to	
demonstrate	the	variable	clinical	course	and	provide	a	brief	review	on	this	disease	entity.
KEYWORDS: Low-grade serous carcinoma; High-grade serous carcinoma; Ovarian	cancer.
INTRODUCTION
	 In	1996,	Burks	et	al.	described	a	peculiar	micropapillary	serous	tumor.1	Eighteen	years	
later,	the	2014	WHO	separated	low-grade	serous	carcinomas	(LGSC)	from	high-grade	serous	
carcinoma	(HGSC)	as	individual	histological	type	rather	than	a	being	just	another	level	in	the	
grading	system. While	both	serous	carcinomas	share	the	same	cell	lineage	(indicated	by	ubiq-
uitous	PAX8	and	WT1	expression),	this	separation	was	based	on	distinct	oncogenic	pathways,	
histopathology	and	clinical	behavior.2,3 The	mean	age	of	women	diagnosed	with	LGSC	is	55	
years,	which	is	six	years	younger	than	HGSC.4	LGSC	account	for	only	4%	of	ovarian	carci-
nomas,	 but	LGSC	 represents	 the	 second	most	 common	histotype	 presenting	with	 advanced	
disease	after	HGSC.	Still	even	in	the	high	stage	setting,	the	ratio	of	LGSC	to	HGSC	is	1:16.5 In 
2004,	Shih	and	Kurman	proposed	the	dualistic	model	of	serous	carcinogenesis.6	The	majority	of	
LGSC	show	mutations	in	KRAS or BRAF	mutations	and	a	lower	proliferation	compared	to	HG-
SC.7	TP53	mutations	are	almost	a	defining	feature	for	HGSC	and	should	not	be	seen	in	LGSC.	
Hence, KRAS/BRAF/TP53	mutations	are	so	specific	that	they	can	be	used	diagnostically.8,9 Yet 
a	diagnosis	can	often	be	made	with	high	reproducibility	based	on	simple	morphology	using	the	
degree	of	nuclear	atypia	in	conjunction	with	architectural	patterns	and	ancillary	immune-his-
tochemistry.10	While	HGSC	are	a	focus	of	research,11	there	are	relatively	few	studies	of	LGSC	
and	no	recurrent	alterations	beyond	KRAS	and	BRAF	have	been	identified.12-14 
	 LGSC	are	commonly	associated	with	metachronous	or	 synchronous	serous	border-
line	tumors/Atypical	Proliferative	Serous	Tumors	(APST).	APST	display	two	distinct	morpho-
logical	phenotypes:	a	hierarchical	branching	pattern	seen	in	the	conventional	type	(not	further	
specified)	or	a	micropapillary	pattern	seen	in	the	micropapillary	variant.	Seven	percent	of	pa-
tients	diagnosed	with	APST	may	 subsequently	develop	LGSC.	A	 recent	 study	 investigating	
five	paired	metachronous	APST	and	LGSC	showed	that	the	same	KRAS mutation	was	already	
present	in	three	preceding	APST,	although	only	in	minor	subclones	by	the	use	of	deep/sensitive	
sequencing,	providing	evidence	that	some	metachronous	APST	and	LGSC	are	clonally	relat-
ed.13	Risk	factors	for	progression	to	LGSC	include	APST	presenting	at	higher	stage,	showing	
microinvasion	or	micropapillary	variant.15	The	micropapillary	variant	shows	an	expression	pro-
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file	more	closely	related	to	LGSC	compared	to	the	conventional	
variant	 and	 could	 be	 therefore	 considered	 as	 the	 noninvasive	
precursor	of	LGSC.16	LGSC	are	commonly	associated	with	syn-
chronous	APST.	A	diagnosis	of	LGSC	is	made	if	frank	invasion	
is	present.	Frank	invasion	is	to	be	distinguished	from	microin-
vasion	 by	 a	 quantitative	 threshold	 of	 an	 invasive	 area	 greater	
than	5	mm	in	extent.	The	classic	histological	pattern	of	invasion	
displays	micropapillae	 in	non-epithelial	 lined	 cleft-like	 spaces	
but	alternative	patterns,	such	as	macropapillary,	solid,	glandular	
with	or	without	extensive	psammomatous	calcifications	(“psam-
mocarcinoma”),	can	occur.17	The	location	of	frank	invasion	can	
be	variable	including	sites	such	as	ovary,	peritoneum	or	lymph	
nodes.18	Noteworthy,	assessment	of	invasion	in	the	peritoneum	
(“invasive	 implants”)	 versus	 noninvasive	 implants	 of	 APST	
quality	is	one	of	the	most	challenging	decisions	to	be	made	in	
gynecological	pathology.
	 Chemotherapy	administration	is	constantly	refined	re-
sulting	in	increased	efficacy	for	HGSC.19 A series of studies from 
MDACC	reported	that	LGSC	are	only	occasionally	responding	
to	 chemotherapy	 and	 highlight	 the	 importance	 of	 surgery.20-22 
A	 recent	 study	 from	 a	 population-based	 series	 challenged	 the	
assumption	that	LGSC	usually	have	a	more	favorable	outcome	
than	HGSC.23,24	We	recently	observed	a	variable	clinical	course	
of	women	diagnosed	with	LGSC.	To	illustrate,	we	present	three	
recent	 cases	 from	our	 institution.	 Institution	 review	 from	Eth-
ics	Committee	was	obtained	for	a	larger	review	on	outcomes	of	
low-grade	serous	carcinoma	of	the	ovary.
Case A
	 A	63-year	old	woman	was	followed	up	since	1995.	She	
underwent	primary	optimal	debulking	surgery;	she	was	staged	
as	a	stage	IIIC,	well	differentiated	papillary	serous	adenocarci-
noma	of	the	ovary.	On	contemporary	pathology	review	the	tu-
mor	showed	7	mm	frank	invasion	in	form	of	macropapillae	in	a	
background	of	serous	borderline	 tumor,	micropapillary	variant	
with	multiple	other	 foci	of	microinvasion.	Postoperatively	she	
received	adjuvant	chemotherapy	with	six	cycles	of	single	agent	
cisplatin	at	60	mg/m2,	she	tolerated	treatment	well	and	remained	
in	remission.	She	recurred	nine	years	later	and	we	managed	her	
with	neoadjuvant	chemotherapy,	three	cycles	of	Q21carboplatin	
at	AUC	of	5	and	Paclitaxel	175	mg/m2	and	secondary	debulking	
procedure.	Optimal	debulking	was	achieved,	which	was	followed	
with	adjuvant	chemotherapy	with	three	cycles	of	Q	21	carbopla-
tin	at	AUC	of	5	and	paclitaxel	175	mg/m2	that	was	tolerated	well.	
She	remained	in	remission	for	two	years.	A	second	recurrence	
in	2006	was	managed	with	two	lines	of	chemotherapy,	initially	
offered	liposomal	doxorubicinat	40	mg/m2	every	4	weeks,	after	
2	cycles	this	was	discontinued	due	to	intolerable	side	effects.	We	
subsequently	switched	her	to	single	agent	topotecan	at	1.25mg/
m2	 for	 5	 days	Q	 21	 for	 four	 cycles.	The	 patient	 opted	 out	 of	
follow	up	and	self	medicated	with	dicholoroacetic	acid	and	tha-
lidomide,	she	remained	stable	for	two	years.	A	third	recurrence	
presented	as	bowel	obstruction.	Following	failure	of	initial	con-
servative	management,	surgical	management	with	a	right	hemi-
colectomy	followed	with	three	lines	of	adjuvant	chemotherapy	
with	single	agent	gemicitabine	at	1	g/m2	every	three	weeks	for	
6	cycles,	tolerated	treatment	well	but	due	to	progressive	disease	
she	was	enrolled	in	a	clinical	trial	unfortunately	she	progressed	
on	the	trial	she	was	offered	single	agent	weekly	paclitaxel	at	80	
mg	/m2	for	6	cycles.	Following	another	two	years	in	remission,	
she	presented	with	a	forth	recurrence	that	was	managed	by	ex-
cision	of	a	left	rectus	muscle	tumor,	retroperitoneal	tumor	and	
partial	cystectomy	and	adjuvant	chemotherapy	with	six	cycles	of	
carboplatin	at	AUC	of	5	and	paclitaxel	175	mg/m2,	she	tolerated	
treatment	well.	Unfortunately	she	developed	progressive	disease	
that	caused	her	to	succumb	18	years	after	the	initial	diagnosis.	
On	pathology	review,	all	her	recurrences	were	classic	LGSC	re-
taining	minor	areas	of	a	macropapillary	pattern	seen	in	the	initial	
case	(Figure	1A).	
Case B
	 A	55-year	old,	initially	presented	with	advanced	ovar-
ian	cancer	and	she	underwent	a	total	abdominal	hysterectomy;	
bilateral	 salpingo	oophorectomy	and	omentectomy	 for	 a	 stage	
IIC	papillary	serous	ovarian	cancer,	optimally	debulked,	she	re-
ceived	six	cycles	of	adjuvant	treatment	with	chemotherapy	with	
six	cycles	of	Q	21	carboplatin	at	AUC	of	5	and	paclitaxel	175	
mg/m2,	she	tolerated	treatment	well.	After	five	years	of	remain-
ing in remission she was discharged from the cancer center and 
followed	up	by	her	family	physician.	Seven	years	after	the	ini-
tial	treatment	she	developed	a	2	cm	swelling	in	her	abdominal	
wall,	which	was	followed	radiologically.	Five	years	later	it	was	
noted	to	double	in	size.	A	biopsy	form	this	revealed	serous	car-
cinoma.	She	had	surgical	debulking	to	microscopic	disease	and	
is	currently	receiving	adjuvant	chemotherapy	with	carboplatin	at	
AUC	of	5	and	paclitaxel	175mg/m2	(Figure	1B).
Case C
	 A	33-year	old	woman	presented	with	abdominal	pain,	
weight	 loss	 and	menstrual	 irregularities.	Medical	 report	 from	
her	home	country	indicated	that	she	underwent	a	left	salpingo-
oophorectomy	and	omentectomy	and	postoperatively	 adjuvant	
chemotherapy	 for	 an	ovarian	 tumor.	On	 review	at	 our	 institu-
tion,	 she	 presented	with	 increasing	 abdominal	 girth,	 pain	 and	
shortness	of	breath.	A	Computerized	Topographical	 (CT)	scan	
revealed	a	 left	sided	pleural	effusion,	 free	 intraperitoneal	fluid	
and	 an	 ill	 defined	 right	 adnexal	 mass.	 Cytology	 from	 ascitic	
fluid	revealed	metastatic	adenocarcinoma	of	ovarian	origin.	She	
received	 three	cycles	of	neoadjuvant	chemotherapy	with	 three	
cycles	of	carboplatin	at	AUC	of	5	and	paclitaxel	175	mg/m2	fol-
lowed	 by	 an	 interval	 debulking	 procedure	where	microscopic	
debulking	was	achieved.	Pathology	from	the	surgical	specimen	
was	reported	as	LGCS	of	the	ovary	(Figure	1C,	and	1D).	Subse-
quently,	she	received	six	cycles	of	adjuvant	chemotherapy	with	
six	cycles	of	carboplatin	AUC	of	5	and	paclitaxel	175	mg/m2.	
Soon	after	completion	of	adjuvant	treatment	she	developed	pro-
gressive	disease	and	was	started	on	second-line	chemotherapy,	
liposomal	 doxorubicin	 40	mg/m2	Q28,	 unfortunately	 she	 died	
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within	eleven	months	of	 initial	diagnosis	and	treatment	(Table	
1).
DISCUSSION
	 LGSC	has	been	traditionally	viewed	as	indolent	disease	
compared	to	HGSC.	In	a	recent	population	based	series,	how-
ever,	 the	long-term	outcome	of	patients	diagnosed	with	LGSC	
was	similar	to	HGSC.25	What	could	be	the	reason	for	those	dif-
ferences?	We	illustrated	a	variable	clinical	course.	Two	of	our	
cases	showed	a	long	term	survival	despite	recurrent	disease	but	
the	third	case	showed	an	aggressive	course.	Hence,	could	above	
cited	studies	could	have	had	a	 selection	bias	 towards	 indolent	
or	aggressive	cases?	Currently,	 there	are	no	reliable	criteria	 to	
assess	prognosis	of	LGSC.	Strong/diffuse	progesterone	receptor	
expression	has	been	suggested	as	 favorable	prognostic	marker	
(RR=0.39,	 95%	 confidence	 interval	 0.018-0.86).4	 The	 G12V	
KRAS	mutation	was	associated	with	unfavorable	outcome	in	a	
small	series.13 Whether	these	biomarker	play	out	in	clinical	prac-
tice	requires	further	validation.	
	 LGSC	is	uncommon	and	only	recently	established.	In	
a	interobserver	reproducibility	study	of	eight	pathologists	from	
European	Nordic	countries,	consistent	diagnosis	of	LGSC	was	a	
major	issue.26	The	main	differential	diagnoses	are	against	APST,	
endometrioid	carcinoma	and	HGSC.	In	a	large	population	based	
series	 from	Denmark,	 only	30%	of	LGSC	were	 confirmed	on	
review	but	12%	of	LGSC	were	reclassified	to	HGSC	and	50%	
to	APST.24	A	favorable	outcome	of	LGSC	can	be	seen	in	cohorts	
that	are	contaminated	by	misclassified	APST.	This	challenge	is	
illustrated	by	our	first	case.	The	initial	tumor	consisted	predomi-
nantly	of	APST	with	foci	of	 frank	 invasion	 just	exceeding	 the	
5	mm	threshold	representing	an	example	for	a	diagnosis	of	an	
LGSC	at	the	lower	end	of	the	spectrum.	All	recurrences	of	this	
Figure 1:  (A) Low-grade serous carcinoma with typical micropapillary low power architecture on the right and variant pattern on the left: 
so called micropapillary inside out pattern. In both pattern papillae are surrounded by non-epithelial lined cleft-like spaces. The nuclei are 
monomorphic lacking significant nuclear atypia (case A). 
(B) Low-grade serous carcinoma with typical micropapillary low power architecture and abundant psammoma bodies, which are often 
seen in low-grade serous carcinoma (so called psammocarcinoma being the extreme variant). The nuclei are monomorphic lacking 
significant nuclear atypia (case B). 
(C) Low-grade serous carcinoma with typical micropapillary low power architecture and monomorphic nuclei (case C)
(D) TP53 immunohistochemistry on specimen from case C displaying TP53 wild type pattern. This pattern is characterized by a heteroge-
neous expression of TP53 with variable intensity in 1-70% of tumor nuclei similar to normal fallopian tube (inset). This pattern is distinct 
from aberrant TP53 expression seen in high-grade serous carcinomas indicative of underlying TP53 mutation, which is characterized by 
either diffuse overexpression (>70% of nuclei displaying strong expression) or complete absence (lack of any expression with positive 
internal control from lymphocytes and fibroblasts, not shown). 
Case A Case B Case C
Age at diagnosis 48 55 33
Stage at diagnosis IIIC IIC IIIC
Time to first recurrence 
(months) 113 175
Progression under 
adjuvant therapy
Time to from diagnosis 
to death (months) 227
Alive with  
disease 11
Time to from first  
recurrence to death 
(months)
114 Alive with  disease NA
WT1 Diffuse Diffuse Diffuse
TP53 Wild type Wild type Wild type
P16 Patchy Patchy Patchy
ER Diffuse Diffuse Diffuse
PR Negative Diffuse Negative
Table 1: Case characteristics.
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case,	however,	were	bona	fida	LGSC	(Figure	1A).	Even	if	 the	
initial	 diagnosis	 is	 disputed,	 the	 survival	 from	 the	 first	 recur-
rence	was	still	greater	than	nine	years.	Another	diagnostic	issue	
is	illustrated	with	the	third	case	that	showed	solid	pattern	in	ad-
dition	 to	 the	 typical	micropapillary	 features	 (Figure	1C).	This	
solid	pattern	raised	the	differential	diagnosis	of	HGSC.	HGSC	
ubiquitously	 harbor	 TP53	 mutations	 and	 contemporary	 TP53	
immuno-histochemistry	serves	as	a	good	surrogate	for	the	TP53 
mutational	statues.	There	was	no	evidence	for	TP53	mutation	by	
immune-histochemistry	(Figure	1D).	
	 Clinical	management	greatly	 influences	 the	course	of	
the	disease.	The	MDACC	group	has	long	been	advocating	for	an	
aggressive	surgical	approach,	which	yields	a	relative	good	out-
come	in	their	patient	series.23	Treatment	alternatives	are	limited.	
Chemotherapy	 can	 induce	 stable	 disease	 and	 achieve	 disease	
control,	but	responses	are	rare.	Similarly,	hormonal	therapy	may	
contribute	to	disease	control	but	response	rates	are	low	(9%)	and	
may	 depend	 on	 the	 PR	 receptor	 status.27	 In	 contrast	 to	 breast	
cancer,	 the	optimal	cut-off	 for	PR	expression	as	prognostic	or	
predictive	marker	for	LGSC	is	not	established.28	PR	expression	
is	present	in	most	LGSC	but	only	a	quarter	expresses	high	levels	
of	PR	and	only	high	level	expression	is	associated	with	unfavor-
able	outcome.4,29 
	 Inhibitors	targeting	the	key	aberrant	pathway	in	LGSC	
have	entered	early	clinical	trials	(e.g.	EUDRACT	Number:	2013-
000277-72).	Selumetinib,	a	MEK	1/2	inhibitor,	was	studied	in	
a	phase	2	trial	of	52	women	with	recurrent	LGSC	achieving	a	
complete	or	partial	response	rate	of	15%	and	65%	of	patients	had	
stable	disease.30	The	responses	were	not	related	to	the	mutational	
status of KRAS or BRAF	raising	the	question	whether	other	func-
tionally	redundant	aberrations	in	the	MAPK	pathway	were	pres-
ent	in	cases	wild	type	for	KRAS or BRAF	that	responded.	It	also	
suggests	that	some	LGSC	with	KRAS or BRAF mutation that did 
not	 respond	may	 have	 additional	 alterations	 inducing	 primary	
resistance	 to	MEK	 inhibitors.	 Further	 comprehensive	molecu-
lar	assessment	combining	different	platform	(whole	genome	se-
quencing,	copy	number	analysis,	methylome,	micro	RNAs)	on	
contemporarily	classified	cases	with	detailed	clinical	follow	up	
is	required	to	increase	our	understanding	of	this	uncommon	dis-
ease.	
	 We	started	 to	manage	LGSC	differently	 from	HGSC.	
In	 the	 initial	 diagnostic	 setting,	we	 prefer	 upfront	 surgery	 for	
LGSC	while	neoadjuvant	chemotherapy	is	an	option	for	HGSC.	
Although	there	are	clinical	hints	for	LGSC	(younger	age,	lower	
CA125),31	we	 push	 for	 a	 tissue	 based	 diagnosis	 preferentially	
an	omental	core	biopsy.	These	biopsies	have	the	advantage	that	
immune-histochemical	 markers	 (panel	 of	 PAX8,	WT1,	 TP53,	
p16)	can	be	more	reliably	compared	to	cell	blocks	obtained	from	
ascites.6	Because	LGSC	has	only	recently	been	recognized,	we	
will	 see	 recurrences	 of	 what	 was	 diagnosed	 well-differentiat-
ed	serous	carcinoma	 in	 the	past	 for	 the	upcoming	years.	Alert	
should	be	raised	if	the	patients	are	younger,	presents	with	mul-
tiple	or	 late	 recurrences	 that	do	not	 respond	 to	 chemotherapy.	
However,	this	can	overlap	with	patients	with	HGSC	carrying	a	
BRCA	germline	mutation	 that	 that	 acquired	 resistance	 to	che-
motherapy.	The	decision	between	recurrence	surgery	for	LGSC	
and	additional	lines	of	chemotherapy	for	HGSC	may	require	a	
contemporary	tissue	based	diagnosis.
	 In	 summary,	 LGSC	 is	 a	 separate	 disease	 entity	 with	
variable	clinical	outcome.	The	variable	outcome	depends	on	the	
biology	 of	 individual	 cases	 (improved	 understanding	 requires	
comprehensive	molecular	characterization	beyond	MAPK	path-
way),	the	clinical	management	(the	relative	resistance	to	chemo-
therapy	leaves	aggressive	surgery	as	the	primary	treatment),	and	
diagnostic	accuracy	(to	 improve	diagnostic	accuracy,	ancillary	
tests	should	be	judiciously	applied).	
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